Estrogenic Activity in the Meat of Broilers Treated with Estrogenes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Reactivity of Human and Equine Estrogen Quinones Towards Purine Nucleosides
S S symmetry Article The Reactivity of Human and Equine Estrogen Quinones towards Purine Nucleosides Zsolt Benedek †, Peter Girnt † and Julianna Olah * Department of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, Szent Gellért tér 4, H-1111 Budapest, Hungary; [email protected] (Z.B.); [email protected] (P.G.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Conjugated estrogen medicines, which are produced from the urine of pregnant mares for the purpose of menopausal hormone replacement therapy (HRT), contain the sulfate conjugates of estrone, equilin, and equilenin in varying proportions. The latter three steroid sex hormones are highly similar in molecular structure as they only differ in the degree of unsaturation of the sterane ring “B”: the cyclohexene ring in estrone (which is naturally present in both humans and horses) is replaced by more symmetrical cyclohexadiene and benzene rings in the horse-specific (“equine”) hormones equilin and equilenin, respectively. Though the structure of ring “B” has only moderate influence on the estrogenic activity desired in HRT, it might still significantly affect the reactivity in potential carcinogenic pathways. In the present theoretical study, we focus on the interaction of estrogen orthoquinones, formed upon metabolic oxidation of estrogens in breast cells with purine nucleosides. This multistep process results in a purine base loss in the DNA chain (depurination) and the formation of a “depurinating adduct” from the quinone and the base. The point mutations induced in this manner are suggested to manifest in breast cancer development in the long run. -
Steroid Sex Hormones Non Steroid Hormones Fig. A1. Chemical
Electronic Supplementary Material (ESI) for Analytical Methods. This journal is © The Royal Society of Chemistry 2015 Steroid sex hormones O OH H H H H H H O Testosterone (T) HO Estrone (E1) OH O H H H H H H O HO 17β-Estradiol (17β-E2) 4-Androstene-3,17-dione (AND) OH OH H OH H H H H H H O HO Nandrolone (NAN) Estriol (E3) OH OH H H H H H H O 17α-Methyltestosterone (17α-MT) HO Ethinylestradiol (EE2) OH O O H HO OH H H H H H H O Prednisolone (PRED) O Progesterone (P) Non steroid hormones HO CH3 HO CH3 H C OH H C OH 3 Diethylstilbestrol (DES) 3 Hexestrol (HEX) Fig. A1. Chemical structure of selected endocrine disruptors. Fig. A2. Scheme of SPE procedure: a) PTFE disks, b) nylon filter membrane. Table A1. Characterization data for mesoporous silicas a Material BET surface Pore volume Pore L0C18 Particle morphology Average particle size 2 -1 3 -1 -1 (m g ) (cm g ) diameter (Å) (mmol C18 g ) (length x wide) SBA-15-C18 796 0.88 76 0.69 Cylindrical 1.4 µm x 750 nm a Amount of octadecyl groups per gram of silica Q3 Q4 Q2 DH 50 0 -50 -100 -150 -200 (ppm) 29 Fig. A3. Si NMR spectrum of SBA-15-C18. 140 0 % Weight Loss T 120 -5 100 s s o L Exothermic Procces 80 t -10 ) h C º g i 60 ( e T W Endothermic Procces -15 % 40 20 -20 0 -25 -20 100 200 300 400 500 600 700 800 T (ºC) Fig. -
Structure and Origin of Uterine and Extragenital L=Ibroids Induced
Structure and Origin of Uterine and Extragenital l=ibroids Induced Experimentally in the Guinea Pig by Prolonged Administration of Estrogens* Alexander Lipschotz, M.D., and Louis Vargas, Jr., M.D. (From Department o/ Experimental Medicine, National Health Service o/the Republic o/Chile, Santiago, Chile) (Received for publication December 13, x94o) The purpose of this communication is to present the These experimentally induced abdominal tumors findings of a detailed microscopical study of the sites present a smooth surface formed of a capsule com- of origin and stages of development of the subserous posed of flattened superficial cells (Plate 2, Figs. 2-A fibroid tumors induced in guinea pigs by prolonged and 2-B). The cells beneath the capsule resemble administration of estrogens. Details of treatment of fibroblasts. These cells have definite boundaries or the animals are given in the explanations of Plates I- 5. they are separated from each other by collagenous Subserous uterine tumors which can be induced in fibers (Plate 4, Fig. ix-C). guinea pigs by prolonged administration of estrogens, The masses of fibroid tumors arising from the apex as described by Nelson (26, 27), were found to be of the uterine horn may enclose the tubes or large fibroids. Lipschiitz, Iglesias, and Vargas (i3, 18, 22) tubal cysts. The demarcation between the muscular have shown that extragenital tumors in the abdominal coat of the tube and the tumor is not always sharp. cavity, induced by estrogens, also were fibroids. The In some instances, especially when the apical fibroid localization of these tumo~:s at various sites on the is small, the tumor is in close contact with an abun- uterus, pancreas, kidney, spleen, etc., have been de- dance of smooth muscle and adipose tissue (Plate 2, scribed by Iglesias (5), Vargas and Lipschiitz (32), Fig. -
Reactivity of Ovariectomised Female Rats After Administration of Injectable Oestrogens by Tem Microscopy
STUDIA UBB CHEMIA, LXI, 2, 2016 (p. 195-203) (RECOMMENDED CITATION) REACTIVITY OF OVARIECTOMISED FEMALE RATS AFTER ADMINISTRATION OF INJECTABLE OESTROGENS BY TEM MICROSCOPY MOCAN-HOGNOGI RADU FLORINa*, COSTIN NICOLAEa, CONSTANTIN CRACIUNb, MALUTAN ANDREIa, TRIF IOANAa, CIORTEA RAZVANa, MIHU DANa ABSTRACT. The purpose of this electrone microscopy study was to identify and specify structural and ultrastructural changes occurring in the vulvar epithelium of ovariectomised female rats, as well as their reactivity to the administration of injectable oestrogens. We used 30 female Wistar white rats, distributed in four groups with 1 control group, to which oestrogenic treatment was administered. The hormone replacement therapy with injectable oestrogens (Estradiol, Estradurin, Sintofolin), at a dose of 0.2 mg/rat/day was administered for 14 days. Afterwards, all animals were sacrificed and vulvar biopsies were taken, which were then processed using optical microscopy (the semithin section technique) and transmission electron microscopy (TEM) techniques. This study showed that injectable oestrogen treatment over a period of 14 consecutive days enables the recovery of each tissue layer, with regard to the structural and ultrastructural modifications arising in ovariectomised female rats. Keywords: oestrogens, optical microscopy, transmission electron microscopy, structure, atrophy, vulvar hyperplasia INTRODUCTION Variations in estrogen levels strongly affect cell growth and metabolism in a variety of tissues including the vulvo-vaginal epithelium, the ovary and uterus. Estradiol is biosynthesized from progesterone, also produced from cholesterol, via intermediate pregnenolone. One principal pathway then converts progesterone to its 17-hydroxy derivative, 17-hydroxyprogesterone, a Second Clinic of Obstetrics and Gynaecology of the “Iuliu Hatieganu” University of Medicine and Pharmacy 32 Clinicilor Str., RO-400006 * Corresponding author: [email protected] b Center of Electron Microscopy of “Babes-Bolyai” University Str. -
Estrogen-Induced Endogenous DNA Adduction
Proc. Natl. Acad. Sci. USA Vol. 83, pp. 5301-5305, July 1986 Medical Sciences Estrogen-induced endogenous DNA adduction: Possible mechanism of hormonal cancer (estradiol/synthetic estrogens/renal carcinoma/Syrian hamster/32P-labeling analysis) J. G. LIEHR*, T. A. AVITTSt, E. RANDERATHt, AND K. RANDERATHtt *Department of Pharmacology, University of Texas Medical Branch, Galveston, TX 77550; and tDepartment of Pharmacology, Baylor College of Medicine, Houston, TX 77030 Communicated by Paul C. Zamecnik, March 24, 1986 ABSTRACT In animals and humans, estrogens are able to but the mechanism of this effect has not been elucidated. In induce cancer in susceptible target organs, but the mecha- view ofthe extensive use ofcompounds with estrogenic activity nism(s) of estrogen-induced carcinogenesis has not been eluci- in human medicine (20, 21) and in agriculture (22) and the dated. A well-known animal model is the development of renal occurrence of estrogenic compounds as contaminants in food carcinoma in estrogen-treated Syrian hamsters. Previous work (22, 23), it is important to define how these compounds cause demonstrated the presence of covalent DNA addition products cancer. (adducts) in premalignant kidneys of hamsters exposed to the A central question to be addressed in this context is whether synthetic estrogen, diethylstilbestrol, a known human carcin- or not estrogens, like the majority of chemical carcinogens, ogen. In the present study, the natural hormone, 178-estradiol, induce covalent DNA alterations in the target tissue of and several synthetic steroid and stilbene estrogens were exam- carcinogenesis in vivo. In the present study, experiments were ined by a 32P-postlabeling assay for their capacity to cause carried out to search for adduct formation in an established covalent DNA alterations in hamster kidney. -
Hormone Replacement Therapy and Osteoporosis
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers— patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services. Systematic Evidence Review Number 12 Hormone Replacement Therapy and Osteoporosis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0018 Task Order No. 2 Technical Support of the U.S. Preventive Services Task Force Prepared by: Oregon Health Sciences University Evidence-based Practice Center, Portland, Oregon Heidi D. Nelson, MD, MPH August 2002 Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) through its Evidence-based Practice Program. With guidance from the third U.S. Preventive Services Task Force∗ (USPSTF) and input from Federal partners and primary care specialty societies, two Evidence-based Practice Centers—one at the Oregon Health Sciences University and the other at Research Triangle Institute-University of North Carolina—systematically review the evidence of the effectiveness of a wide range of clinical preventive services, including screening, counseling, immunizations, and chemoprevention, in the primary care setting. -
Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol Plus Hexestrol*T
Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol plus Hexestrol*t A. ANGRIST, P. CAPURRO, AND B. MOUMGIS (Department of Pathology, Albert Einstein College of Medicine of Yeshiva University, New York 61, N.Y.) SUMMARY The effects of estrogens were studied with and without foreign body (rough glass beads and paraffin pellets) on the metaplasia of the bladder of rats on stock main tenance diet and on a vitamin A-deficient diet. Estradiol increased the degree of metaplasia in the bladder of rats when combined with vitamin A deficiency and/or foreign body stimulation. Estradiol affected bladder epithelium already made squamous more effectively than it did the normal transitional uroepithelium. A high dose of hexestrol, when added to estradiol, showed no enhance ment of the degree of metaplasi.a by estradiol benzoate in the bladder of the rat. The combination of vitamin A deficiency, foreign body in situ, and estrogenadminis tration was an effective means of obtaining keratinizing squamous metaplasia in the urinary bladder for studies of its developmental and reversal changes. In a previous presentation (4) the relation of The animals were divided into the following different forms of foreign-body irritation and of groups (the number of rats surviving with tissue vitamin A deficiency to squamous metaplasia in for study and the total number in each group mi the bladders of rats was reported. It is also known tinily are given following each group): that estrogens will cause squamous metaplasia. I. Stock diet + estradiol (6 survivals/lI rats) The metaplasia following estrogen administration II. -
Marrakesh Agreement Establishing the World Trade Organization
No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX -
Use of Estrogen-Dihydropyridine Compounds For
Europaisches Patentamt J European Patent Office © Publication number: 0 220 844 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION © Application number: 86307536.2 © int. ci.<: A61K 31/57 A61 K , 31/565 , A61K 31/44 © Date of filing: 01.10.86 The title of the invention has been amended © Applicant: UNIVERSITY OF FLORIDA (Guidelines for Examination in the EPO, A-lll, 207 Tigert Hall 7.3). Gainesville Florida 32611 (US) @ Inventor: Bodor, Nicholas S. ® Priority: 22.10.85 US 790159 7211 Southwest 97th Lane Gainesville Florida 32608(US) © Date of publication of application: Inventor: Estes, Kerry S. 06.05.87 Bulletin 87/19 5604 Southwest 83rd Drive Gainesville Florida 32608(US) © Designated Contracting States: Inventor: Simpkins, James W. AT BE CH DE ES FR GB GR IT LI LU NL SE 1722 Northwest 11th Road Gainesville Florida 32605(US) © Representative: Pendlebury, Anthony et al Page, White & Fairer 5 Plough Place New Fetter Lane London EC4A 1HY(GB) © Use of estrogen-dihydropyridlne compounds for weight control. © The invention provides the use of a compound of the formula [E-DHC] (I) or a non-toxic pharmaceutically acceptable salt thereof, wherein [E] is an estrogen and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal form of a dihydropyridines*pyridinium salt redox carrier in the preparation of a medicament for controlling mammalian body weight. Novel compositions for weight control comprising a compound of formula (I) or its salt are also disclosed. A preferred compound for use herein is an I estradiol derivative, namely, 1 7/3-[(1 -methyl-1 ,4-dihydro-3-pyridinyl)carbonyloxy]estra-1 ,3,5(1 0)-trien-3-ol. -
UNITED STATES PATENT OFFICE 2,385,853 Processes Foe PRODUCING Hormones Stockton G
Patented Oct 2, 1945 2,385,853 UNITED STATES PATENT OFFICE 2,385,853 PROCESSEs FoE PRODUCING HoRMoNEs Stockton G. Turnbul, Jr., Wilmington, Del, as sinor to E. I. du Pont de Nemours & Company, Wilmington, Del, a corporation of Delaware NoDrawin. Application August 17, 1943, Serial No. 498,984 2 Claims. (CL 260-619) This invention relates to new and inexpensive 150-watt projector flood lamp, a solution of 9.6 processes for producing hormones and in partica parts of bromine in 50 parts by volume of carbon ular synthetic estrogens, tetrachloride was added dropwise over 3.5 hours It is an object of this invention to produce hors in Such a Way that the heat evolved in the reac mones by means of a new and relatively inexpen tion maintained the reaction mixture at a gentle sive process. A further object is to produce syn reflux, Hydrogen bromide was evolved. The thetic estrogens by a simple and easily controlled pale yellow solution was then cooled and ex process. A still further object is to produce hor tracted twice with 5% sodium sulfite and was mones by a process which avoids many of the dis then dried over sodium sulfate and concentrated advantages of the prior art processes. Addi 10 under vacuum. The 20 parts of oil and crystals . tional objects will become apparent from a con thus obtained was slurried in cold acetone which sideration of the following description and gave 7 parts of white crystals. Upon recrystal claims. lization from ethyl acetate the 3,4-di-Cp-anisyl)r These objects are attained in accordance with 3,4-dibromohexane was obtained as white crys the hereinafter described invention wherein a tals tnat darkened sligntly at 115° C. -
有限公司 API Antineoplastic Agents
® 伊域化學藥業(香港)有限公司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICK -VIC 伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com API Antineoplastic Agents Product Highlight The following is a selection of products we have sourced and supplied to our customers globally. For detailed specifications, certificates of analysis, supply position, and tailored pricing, please contact us at [email protected] . For any unlisted products that you require, feel free to contact us for support. We can source or custom manufacture at your specification. Product Code CAS Product Name PH-3107DA 522-17-8 (-)-DEGUELIN PH-4360CF 989-51-5 (-)-EPIGALLOCATECHIN GALLATE MIS-6071 32981-86-5 10-DEACETYLBACCATIN III (REFERENCE GRADE) MIS-5741 78432-77-6 10-DEACETYLPACLITAXEL (REFERENCE GRADE) PH-0441BA 19685-09-7 10-HYDROXYCAMPTOTHECIN 64439-81-2 (UNSPECIFIED ISOMER) PH-0441BC 19685-09-7 10-HYDROXYCAMPTOTHECIN (REFERENCE GRADE) 64439-81-2 (UNSPECIFIED ISOMER) PH-3394A 533-67-5 2-DEOXY-D-RIBOSE PH-1956DA 951-78-0 2'-DEOXYURIDINE PH-0865F 38390-45-3 3',4'-ANHYDROVINBLASTINE MIS-10676 75567-37-2 3-INGENYL ANGELATE (REFERENCE GRADE) 849146-39-0 Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 57 Product Code CAS Product Name PH-1578EK 2498-50-2 4-AMINOBENZAMIDINE DIHYDROCHLORIDE PH-1541D 23363-35-1 4'-DEMETHYLEPIPODOPHYLLOTOXIN-9 BETA-GLUCOPYRANOSIDE PH-4586B 1716-12-7 -
Steroidal Estrogens
FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.